ADH4
All-trans-retinol dehydrogenase [NAD
As of the edition of 20 October 2026, ADH4 (all-trans-retinol dehydrogenase [NAD, UniProt P08319) has 1 drug tested at it and 0 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P08319
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Inside the cell
- Solved structures
- 1
Drugs at this target
| Status | Count |
|---|---|
| Withdrawn from market | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Nitrefazole | Withdrawn from market | No phase stated | none listed |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Total on the list | 0 |